NewAmsterdam Pharma Company NV
NASDAQ:NAMS
NewAmsterdam Pharma Company NV
Cash from Operating Activities
NewAmsterdam Pharma Company NV
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Cash from Operating Activities
€8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Pharming Group NV
AEX:PHARM
|
Cash from Operating Activities
-$2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash from Operating Activities
-€38.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Uniqure NV
NASDAQ:QURE
|
Cash from Operating Activities
-$128.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-33%
|
|
argenx SE
XBRU:ARGX
|
Cash from Operating Activities
-$420.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
Merus NV
NASDAQ:MRUS
|
Cash from Operating Activities
-$149.9m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
See Also
What is NewAmsterdam Pharma Company NV's Cash from Operating Activities?
Cash from Operating Activities
8m
EUR
Based on the financial report for Dec 31, 2022, NewAmsterdam Pharma Company NV's Cash from Operating Activities amounts to 8m EUR.